ฝัง
- เผยแพร่เมื่อ 27 ส.ค. 2024
- Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study.
ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were randomised 2:1 to receive either oral acoramidis 800mg twice daily, or placebo for 30 months. Patients had the option tafmidis after 12 months.
The analysis of primary endpoints, including Finkelstein-Schoenfeld hierarchy of ACM, CVH, NT-proBNP, and 6MWD, showed highly significant results. The win ratio was 1.8 with a p-value of less than 0.0001. In 58% of cases where there was a tie in the win ratio, ACM and CVH factors combined were used to break the tie.
Questions:
1. What are the unmet needs of patients and currently available treatments for ATTR?
2. Can you summarise the mechanism of action of the study drug?
3. What was the study design, patient population and outcome measures?
4. What are the key results?
5. Were there any safety events?
6. What are the take-home messages?
7. What are the next steps?
Recorded on-site at ESC Congress 2023, Amsterdam.
Visit Radcliffe Cardiology: www.radcliffec...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on Twitter: / radcliffecardio
